The estimated Net Worth of Michelle Robertson is at least $1.43 Million dollars as of 11 May 2023. Ms Robertson owns over 949 units of Editas Medicine Inc stock worth over $402,986 and over the last 6 years she sold EDIT stock worth over $381,311. In addition, she makes $647,262 as CFO, Principal Accounting Officer, and Treasurer & Assistant Sec. at Editas Medicine Inc.
Ms has made over 15 trades of the Editas Medicine Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 949 units of EDIT stock worth $9,367 on 11 May 2023.
The largest trade she's ever made was exercising 9,750 units of Editas Medicine Inc stock on 17 October 2019 worth over $36,855. On average, Ms trades about 1,143 units every 50 days since 2018. As of 11 May 2023 she still owns at least 106,610 units of Editas Medicine Inc stock.
You can see the complete history of Ms Robertson stock trades at the bottom of the page.
Michelle Robertson is the CFO, Principal Accounting Officer, Treasurer & Assistant Sec. at Editas Medicine Inc.
As the CFO, Principal Accounting Officer, and Treasurer & Assistant Sec. of Editas Medicine Inc, the total compensation of Ms Robertson at Editas Medicine Inc is $647,262. There are 3 executives at Editas Medicine Inc getting paid more, with Cynthia Collins having the highest compensation of $14,489,700.
Ms Robertson is 54, she's been the CFO, Principal Accounting Officer, and Treasurer & Assistant Sec. of Editas Medicine Inc since . There are 15 older and 3 younger executives at Editas Medicine Inc. The oldest executive at Editas Medicine Inc is Dr. George McDonald Church Ph.D., 67, who is the Co-Founder & Scientific Advisory Board Member.
Michelle's mailing address filed with the SEC is C/O VERASTEM, INC.,, 117 KENDRICK ST., SUITE 500, NEEDHAM, MA, 02494.
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr, and Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
Editas Medicine Inc executives and other stock owners filed with the SEC include: